News & Videos - DAXOR CORP. - Page 2

You are currently viewing all stock exchange news of the financial instrument DAXOR CORP. regarding all markets in all languages.

> News GlobeNewsWire published a news.

DXR

Daxor Corporation Appoints John L. Jefferies, M.D. as Chief Medical Officer • • GlobeNewsWire • ETF

Oak Ridge, TN, June 05, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces the appointment of Dr. John L. Jefferies, M.D., M.B.A., M.P.H., F.A.C.C., F.A.H.A., F.A.A.P., F.H.F.S.A., F.E.S.C., F.R.C.P.E., as Chief Medical Officer. As part of his new responsibilities, Dr. Jefferies will leverage his extensive expertise to advise Daxor on strategic clinical and medical affairs matters and to facilitate the collaboration...

Thank you Chart

> News GlobeNewsWire published a news.

DXR

New Studies Prove the Clinical Benefits of Daxor’s Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion • • GlobeNewsWire • ETF

Data Presented at the American College of Cardiology Scientific Sessions; Research Letter Published in the Prestigious American Heart Journal Oak Ridge, TN, April 16, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces two new studies validating the clinical benefits of blood volume analysis (BVA) as a more precise measurement of congestion in ambulatory heart failure (HF) patients. Data from both studies...

Thank you Chart

> News GlobeNewsWire published a news.

DXR

DAXOR CORPORATION TO EXHIBIT AT THE MEDAXIOM CARDIOVASCULAR TRANSFORUM CONFERENCE SPRING’24 TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXOR’S BLOOD VOLUME DIAGNOSTIC (BVA-100™) • • GlobeNewsWire • ETF

The Premier Event for Cardiovascular Industry Leaders and Clinicians Oak Ridge, TN, April 15, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today it will be exhibiting at the MedAxiom CV Transforum Spring’24 Conference being held at the Atlanta Marriott Marquis in GA, from April 18-20, 2024. The CV Transforum conference, hosted by MedAxiom, an American College of Cardiology company, unites cardiovascular thought...

Thank you Chart

> News GlobeNewsWire published a news.

DXR

Daxor Corporation Announces New Hospital Account at Leading Chicago Hospital • • GlobeNewsWire • ETF

450-Bed Hospital Purchases BVA-100 ™ Blood Volume Analyzer to Launch H eart Failure P rogram Oak Ridge, TN, April 10, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology today announces the purchase of Daxor’s BVA-100 ™ at a 450-bed teaching hospital in the greater Chicago area. “Hospitals are utilizing our BVA diagnostic to save money by reducing length of stay while improving Hospital Readmissions Reduction Program (HRRP)...

Thank you Chart

> News GlobeNewsWire published a news.

DXR

Daxor Corporation to Exhibit at the American College of Cardiology for ACC.24 • • GlobeNewsWire • ETF

Oak Ridge, TN, April 01, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR) , the global leader in blood volume measurement technology, today announces it will be exhibiting at the American College of Cardiology (ACC.24) at the Georgia World Congress Center in Atlanta, GA, April 6 – 8, 2024. “ACC.24 is considered the premier cardiology exposition in the Americas, offering a prime opportunity for Daxor to broaden its reach within the entire cardiovascular community,” said Michael...

Thank you Chart

> News GlobeNewsWire published a news.

DXR

Daxor Corporation Acquires Volumex® and Megatope® From Its Existing Supplier Along With Glofil® to Enhance Existing Suite of Diagnostics • • GlobeNewsWire • ETF

Expected to Improve Margins and Increase Revenue Streams Oak Ridge, TN, March 25, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR) , the global leader in blood volume measurement technology, announces today it has entered into a definitive agreement to acquire exclusive and worldwide rights and intellectual property to manufacture from its existing supplier for Volumex and Megatope from privately-held Iso-Tex Diagnostics, Inc. Daxor has also acquired the exclusive rights to Glofil, a...

Thank you Chart

> News GlobeNewsWire published a news.

DXR

Daxor Corporation to Hold Investor Call Discussing Fiscal Year 2023 Financial Results and Corporate Update on March 25, 2024 • • GlobeNewsWire • ETF

Oak Ridge, TN, March 22, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR) , the global leader in blood volume measurement technology, announces an investor call to be held on Monday, March 25, 2024, at 4:00 p.m. ET. President and CEO Michael Feldschuh and CFO Robert Michel will also host the call to review financial results and provide an update on corporate developments. After Management’s presentation, there will be an opportunity for Q&A. Investors are welcome to submit questions in...

Thank you Chart

> News GlobeNewsWire published a news.

DXR

Daxor Corporation Reports Increase in NAV to $7.08 Per Share and 31.8 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023 • • GlobeNewsWire • ETF

Strong Start to 2024 with Unaudited Revenue Climbing 229.1% in First Two Months of 2024 YoY Oak Ridge, TN, March 18, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR) , the global leader in blood volume measurement technology, announces today the filing of its Annual Report to Shareholders on Form N-CSR, disclosing its schedule of portfolio holdings as of December 31, 2023. Management reported a NAV of $7.08 per share for fiscal 2023 versus $6.75 for the comparable period in 2022. The...

Thank you Chart

> News GlobeNewsWire published a news.

DXR

Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders • • GlobeNewsWire • ETF

Oak Ridge, TN, March 18, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology today issued a corporate update in a Letter to Shareholders filed in its certified shareholder report on Form N-CSR on March 15, 2023 from CEO & President, Michael Feldschuh. Dear Fellow Shareholder: "Concentrate all your thoughts upon the work in hand. The sun's rays do not burn until brought to a focus." - Alexander Graham Bell We have never been more...

Thank you Chart

> News GlobeNewsWire published a news.

DXR

Daxor Announces Sales to Three New Hospitals Furthering Expansion of Its User Base • • GlobeNewsWire • ETF

Oak Ridge, TN, March 11, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology today announces the expansion of blood volume analysis (BVA) in three new hospitals through new analyzer purchases, and the utilization of Daxor’s ezBVA Lab service. These new acquisitions further fuel BVA sales growth and underscore its clinical relevance. New client and services wins include: BVA analyzer purchase at a 735-bed non-profit, tertiary,...

Thank you Chart

> News GlobeNewsWire published a news.

DXR

Multi-Center Study Presented by Duke at Heart Failure Therapeutics Conference Highlights Daxor’s Unique Clinical Utility for Heart Failure Patients • • GlobeNewsWire • ETF

Only Daxor’s BVA Diagnostic Was Shown to Accurately Reflect Blood Volume Compared to Inferior Surrogates Oak Ridge, TN, March 08, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces new data from Duke University Medical Center validating the benefits of blood volume analysis (BVA) in optimizing individualized therapy for heart failure patients with impaired renal function. Data were presented on 259 patients from...

Thank you Chart

> News GlobeNewsWire published a news.

DXR

Daxor Corporation to Exhibit at the Technology and Heart Failure Therapeutics Conference • • GlobeNewsWire • ETF

Oak Ridge, TN, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announces it will be exhibiting at the Technology and Heart Failure Therapeutics Conference (THT), which brings together the world’s leading experts in heart failure innovations at the Westin Boston Seaport in Boston, Massachusetts March 4-6, 2024. “We are excited to showcase Daxor’s innovative blood volume analysis (BVA) diagnostic as a solution...

Thank you Chart

> News GlobeNewsWire published a news.

DXR

Daxor Corporation Starts 2024 with Ongoing Growth in New Blood Volume Analyzer Acquisitions • • GlobeNewsWire • ETF

Oak Ridge, TN, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology today announces two significant new customer transactions with Daxor’s BVA-100 ™ (Blood Volume Analyzer) in January, marking a strong start to 2024. New wins include: Four-year lease agreement for the BVA analyzer at an award-winning network of 24 affiliated hospitals in Mississippi, West Tennessee, and East Arkansas with a reach into Kentucky, Missouri,...

Thank you Chart

> News GlobeNewsWire published a news.

DXR

Daxor Corporation Closes Q4 2023 with Growth in New Sales to Hospital Systems and Increased Utilization of its BVA-100® Blood Volume Diagnostic Across the U.S. at Existing Accounts • • GlobeNewsWire • ETF

Daxor's ezBVA Lab Service Plays a Significant Role in Driving Growth and Fostering Widespread Adoption Oak Ridge, TN, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology today announces the expansion of blood volume analysis (BVA) through new analyzer purchases and the utilization of Daxor’s ezBVA Lab service. These Q4 2023 initiatives have all played a significant role in driving the growth and the widespread adoption of...

Thank you Chart

> News GlobeNewsWire published a news.

DXR

Daxor Corporation to Exhibit at the Society of Nuclear Medicine and Molecular Imaging Mid-Winter and American College Nuclear Medicine Annual Meeting • • GlobeNewsWire • ETF

Oak Ridge, TN, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR) , the global leader in blood volume measurement technology, today announces it will be exhibiting at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Mid-Winter and American College Nuclear Medicine (ACNM) Annual Meeting at the Hilton Orlando Lake Buena Vista in Orlando, FL, February 1-3, 2024. "This conference presents an exciting opportunity to raise awareness and educate SNMMI and ACNM members about...

Thank you Chart

> News GlobeNewsWire published a news.

DXR

Daxor Corporation to Exhibit at the Society for Critical Care Medicine 2024 Critical Care Congress • • GlobeNewsWire • ETF

Oak Ridge, TN, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR) , the global leader in blood volume measurement technology, today announces it will be exhibiting at the Society for Critical Care Medicine (SCCM) 2024 Critical Care Congress at the Phoenix Convention Center in Phoenix, AZ from January 21 through January 23, 2024. Highlighting the significance of this meeting as the leading critical care conference globally and presenting a substantial opportunity for Daxor to...

Thank you Chart

> News GlobeNewsWire published a news.

DXR

DAXOR AWARDED ADDITIONAL NEW PATENT FOR SMART BLOOD VOLUME GUIDANCE TECHNOLOGY TO IMPROVE TREATMENT AND OUTCOMES • • GlobeNewsWire • ETF

Patent Covers Systems and Methods For Algorithmic Treatment Across a Spectrum of Conditions Oak Ridge, TN, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces that the United States Patent and Trademark Office has issued the company a second patent (U.S. Patent No. 11,862,311 B2), safeguarding a distinctive clinical guidance system for blood volume management. This system utilizes unique blood volume metrics...

Thank you Chart

> News GlobeNewsWire published a news.

DXR

Daxor Corporation Submits Dual 510(k)/CLIA-waiver Application to the FDA for Its Advanced Next-Generation Blood Volume Analyzer • • GlobeNewsWire • ETF

The New BVA System is Designed to be Significantly Faster, Simpler and Give Results at the Bedside Oak Ridge, TN, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it has submitted its next-generation blood volume analyzer - Daxor BVA - to the U.S. Food and Drug Administration (FDA) via the 510(k)/CLIA-waiver dual submission pathway. Potential clearance is expected during the first half of 2024. The...

Thank you Chart

> News GlobeNewsWire published a news.

DXR

New Randomized Controlled Trial Demonstrates the Efficacy of Daxor’s BVA Guided-Care in Heart Failure Patients • • GlobeNewsWire • ETF

Data From Study Funded by NIH Presented at the American Heart Association Annual Meeting Oak Ridge, TN, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces the presentation of data from a Phase I National Institute of Health (NIH) sponsored randomized control trial (RCT) from two Veterans Affairs Medical Centers (Boston , Minneapolis), validating treatment decisions guided by the Company’s BVA-100 ®...

Thank you Chart

> News GlobeNewsWire published a news.

DXR

Daxor Corporation Awarded New Patent for Remote Monitoring of Blood Volume • • GlobeNewsWire • ETF

Patent Covers Novel Optimization of Care by Remote Monitoring Devices Including Smartwatches Oak Ridge, TN, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces that Daxor was recently granted a patent for a system to provide remote blood volume monitoring after initial testing with Daxor BVA-100 ® (Blood Volume Analyzer) diagnostic. This U.S. patent number (US 11,801,002 B2) adds to our existing portfolio...

Thank you Chart